Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Investigators at University of Tor Vergata have published new data on acute myeloid leukemia
December 2nd, 2008
" Despite the identification of several baseline prognostic indicators, the outcome of patients with acute myeloid leukemia (AML) is generally heterogeneous. The effects of autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation," investigators in Rome, Italy report. "Minimal residual disease (MRD) states may be essential for assigning patients to therapy-dependent risk categories. Patients and Methods By multiparametric flow cytometry, we assessed the levels of MRD in 142 patients with AML who achieved complete remission after intensive chemotherapy. A level of 3.5 x 10(-4) residual leukemia cells (RLCs) after consolidation therapy...
Source: Cancer Weekly (2008-12-02)
|
